Primary cutaneous anaplastic large cell lymphoma
diseaseOn this page
Also known as ALCL, cutaneousanaplastic large-cell lymphoma, primary cutaneous typeC-ALCLprimary anaplastic large cell lymphoma of skinprimary anaplastic large cell lymphoma of the skinprimary C-ALCLprimary cutaneous CD30 Positive anaplastic large cell lymphomaprimary cutaneous CD30+ ALCLprimary cutaneous CD30+ anaplastic large cell lymphomaregressive atypical histiocytosis
Summary
Primary cutaneous anaplastic large cell lymphoma (MONDO:0017598) is a cancer and 6 clinical trials. Top therapeutic interventions include bexarotene, brentuximab vedotin, and cyanocobalamin. A subtype of primary cutaneous T-cell non-Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: Unknown (Europe)
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | primary cutaneous anaplastic large cell lymphoma |
| Mondo ID | MONDO:0017598 |
| MeSH | D054446 |
| Orphanet | 300865 |
| ICD-11 | 1972636482 |
| NCIT | C6860 |
| UMLS | C1301362 |
| MedGen | 266255 |
| GARD | 0021247 |
| MedDRA | 10065863 |
| Is cancer (heuristic) | yes |
Also known as: ALCL, cutaneous · anaplastic large-cell lymphoma, primary cutaneous type · C-ALCL · primary anaplastic large cell lymphoma of skin · primary anaplastic large cell lymphoma of the skin · primary C-ALCL · primary cutaneous CD30 Positive anaplastic large cell lymphoma · primary cutaneous CD30+ ALCL · primary cutaneous CD30+ anaplastic large cell lymphoma · regressive atypical histiocytosis
Disease family
This is a subtype of primary cutaneous T-cell non-Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › primary cutaneous lymphoma › primary cutaneous T-cell non-Hodgkin lymphoma › primary cutaneous anaplastic large cell lymphoma
Related subtypes (4): mycosis fungoides, Sezary syndrome, mycosis fungoides variant, primary cutaneous gamma-delta t-cell lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01578499 | PHASE3 | COMPLETED | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) |
| NCT03409432 | PHASE2 | COMPLETED | Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma |
| NCT01134341 | PHASE1 | COMPLETED | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma |
| NCT01787409 | Not specified | ACTIVE_NOT_RECRUITING | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency |
| NCT05978141 | Not specified | RECRUITING | A Registry for People With T-cell Lymphoma |
| NCT02652715 | Not specified | COMPLETED | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEXAROTENE | 4 | 2 |
| BRENTUXIMAB VEDOTIN | 4 | 2 |
| CYANOCOBALAMIN | 4 | 1 |
| PRALATREXATE | 4 | 1 |
| CHEMBL4303681 | 0 | 1 |
| VITAMIN B12 | 0 | 1 |